The IMPACT and related targeted prostate cancer screening studies integrate germline BRCA1/2 and mismatch repair variants with tailored PSA screening protocols, structured pre- and post-test counseling, and systematic cascade testing in at-risk men across multiple countries, demonstrating long-term engagement and earlier detection in high-risk carriers [19,20]. This evidence concerns the gene BRCA1 and prostate carcinoma.